Mid-Titration, Emotionally Unavailable Until Q2

Kronk concedes: 'currently up-dosing a triple agonist' is a more honest Hinge prompt than the fourteenth identical taco confession.

Filed under Survodutide ·PT-141 (Bremelanotide) ·Enclomiphene · #glp-1 ·#dating-app ·#cope

Active Compounds

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

PT-141 (Bremelanotide) · Melanocortin Receptor Agonist

An FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, also studied for broader sexual dysfunction.

Enclomiphene · Selective Estrogen Receptor Modulator

The active isomer of clomiphene, a selective estrogen receptor modulator (SERM) that raises testosterone while preserving fertility. Not FDA-approved as a standalone drug, but widely available through compounding pharmacies.

RX: Survodutide · PT-141 (Bremelanotide) · Enclomiphene
Dosage: one prompt answer
Half-life: until Q2
Source: manual
Tags: glp-1 , dating-app , cope
Stamped: 2026-07-09 · Cycle 028
Lot #: LOT-20260709T13:58:49.735Z